Business Wire4d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The American Journal of Managed Care5d
FDA Approves Ranibizumab Implant in Treatment of DME
The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...
ophthalmologytimes5d
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Hosted on MSN5mon
Innovative CTAK procedure offers hope for patients with corneal diseases
One of the great things about this is that in the previous transplant, the biggest risk was a corneal injection, which your own body would recognize as not yours and start to attack it.
Pharm Exec4d
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Healio4d
FDA approves Susvimo for diabetic macular edema
The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was ...
Endocrinology Advisor3d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.